Skip to content
DataLookout
Menu

TRACE-AANCT07930793

Aplastic Anemia Life-Course Cohort Study

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Hematologic response
Timeframe: Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year.
Clonal evolution
Timeframe: Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year.
Treatment related adverse events
Timeframe: Within 10 years after allo-HSCT; within 6 months after IST

Arms and interventions

TRACE-AA

1. Describe real-world treatment patterns and clinical outcomes in AA, including IST, HSCT, and other therapies. 2. Evaluate treatment-related adverse events and safety, particularly complications of ATG/ALG-based IST and HSCT. 3. Characterize longitudinal hematopoietic and immune reconstitution after drug therapy or HSCT, including immune-cell subsets, clonal T cells, immune biomarkers, and hematopoietic recovery. 4. Estimate the cumulative incidence and trajectories of clonal hematopoiesis after IST, including cytogenetic and molecular abnormalities and PNH clones. 5. Assess prognosis, including treatment discontinuation, relapse, clonal evolution, quality of life, and long-term survival.

Other: A combined retrospective and prospective observational follow-up

Sites

1 site in 1 country

  • Red Blood Cell Diseases Center and Regenerative Medicine CenterTianjin, Tianjin Municipality, China